Epithalon
A synthetic tetrapeptide studied for its ability to activate telomerase — the enzyme that maintains telomere length. It's one of the most intriguing anti-aging peptides, but the evidence comes with important caveats.
Epithalon (Ala-Glu-Asp-Gly) is a synthetic version of epithalamin, a peptide produced by the pineal gland. It was developed by Vladimir Khavinson in Russia and studied for its ability to activate telomerase — the enzyme that rebuilds the protective caps (telomeres) on your chromosomes. Shorter telomeres are associated with biological aging.
Often used by: Longevity enthusiasts interested in telomere biology, people exploring anti-aging peptide protocols, biohackers willing to work with emerging evidence.
Dive deeper into the researchCommon side effects
- Injection site reactions (redness, mild pain)
- Temporary changes in sleep patterns (pineal gland connection)
- Very limited safety data — unknown long-term effects
What does Epithalon do?
Every time your cells divide, the telomeres — protective caps on the ends of your chromosomes — get a little shorter. When they get too short, cells stop dividing properly, leading to aging and disease. Telomerase is the enzyme that rebuilds telomeres, but its activity declines with age.
Epithalon appears to reactivate telomerase in certain cell types, potentially slowing or partially reversing this aspect of cellular aging. In cell culture studies, it increases telomerase activity and extends the replicative lifespan of human cells. In animal studies (primarily by Khavinson’s group), it extended lifespan in mice and improved biomarkers of aging.
It also seems to regulate the pineal gland and melatonin production, which may independently contribute to its anti-aging effects through circadian rhythm optimisation.
Who uses it?
- Longevity enthusiasts — interested in telomere maintenance as an anti-aging strategy
- Anti-aging protocol users — often combined with other longevity interventions
- Those tracking biological age — using epigenetic clocks or telomere tests to monitor effects
- Melatonin and sleep optimisers — epithalon’s pineal effects may improve natural melatonin production
What to know before trying
Most epithalon research comes from one group (Khavinson’s lab in Russia). While the body of work is extensive, independent replication by Western labs is limited. The telomerase activation mechanism is biologically plausible, but the strength of human evidence is still emerging.
Typical protocol: 5–10 mg subcutaneous injection daily for 10–20 consecutive days. This cycle is repeated 1–2 times per year. This is not a daily indefinite protocol.
Measuring effects: Consider baseline telomere length testing or epigenetic age testing (GlycanAge, TruDiagnostic) before and after a cycle. Without objective measurement, there’s no way to know if it’s working for you specifically.
The cancer question: Telomerase activation raises a theoretical concern — cancer cells also use telomerase to become immortal. Current evidence doesn’t show epithalon promotes cancer, and some Khavinson studies suggest anti-tumour effects, but this remains an area of active debate.
Want to track if your peptide protocol is working?
eterni connects your labs, supplements, and retests — so you can see real data, not just guesswork.
Get early accessFrequently Asked Questions
Does epithalon actually extend telomeres?
In cell culture, epithalon activates telomerase and extends replicative lifespan. In animal studies from Khavinson’s group, it extended lifespan in mice. Human evidence is limited to small Russian studies showing telomere maintenance. Independent Western replication is needed for stronger confidence.
How is epithalon administered?
Subcutaneous or intramuscular injection, typically 5–10 mg daily for 10–20 consecutive days. This cycle is repeated once or twice per year. It’s not a continuous daily protocol. Reconstitute lyophilised powder with bacteriostatic water.
Is epithalon safe?
Available data (mostly from Russian studies) shows a favourable safety profile with no serious adverse events reported. The theoretical concern about telomerase activation and cancer risk has not been confirmed in studies. However, long-term safety data in humans is genuinely limited.
Can I measure if epithalon is working?
Yes — telomere length testing (via blood test) or epigenetic age testing (GlycanAge, TruDiagnostic) before and after a cycle can provide objective data. Without testing, you’re relying on subjective reports, which are unreliable for something as gradual as biological aging.
How it works in your body
Epithalon activates telomerase reverse transcriptase (hTERT) — the catalytic subunit of telomerase responsible for adding TTAGGG repeats to chromosome ends. It also modulates the pineal gland’s production of melatonin, potentially improving circadian rhythm regulation. The pineal connection may be related to its peptide bioregulator properties — Khavinson’s broader framework of using short peptides to “reset” specific organ functions.
What the studies show
- Cell studies: Telomerase activation and extended replicative lifespan in human somatic cells
- Animal studies: Extended lifespan in mice (Khavinson group), improved biomarkers of aging
- Human studies: Small Russian studies showing telomere maintenance and improved biomarkers. Limited Western replication.
- Pineal function: Restoration of melatonin production patterns in aging subjects
What to monitor
- Telomere length — baseline and post-cycle (allow 3–6 months for measurable change)
- Epigenetic age — optional but provides broader biological age assessment
- Sleep quality — pineal effects may improve natural melatonin production
- General bloodwork — CBC, metabolic panel to ensure no adverse trends
Side effects & safety
Epithalon has limited but generally favourable safety data:
- Injection site reactions — redness, mild pain, or swelling at the injection site. Standard for subcutaneous injections.
- Sleep changes — some users report altered sleep patterns during the injection cycle, possibly related to pineal gland effects. Usually normalises.
- Fatigue — mild tiredness reported by some during the injection cycle.
- Telomerase and cancer (theoretical) — cancer cells use telomerase to become immortal. Epithalon activates telomerase in normal cells. Current evidence doesn’t show epithalon promotes cancer, but the theoretical concern is not yet fully resolved.
- Unknown long-term effects — no long-term human safety studies exist. The consequences of periodic telomerase activation over decades are genuinely unknown.
Who should avoid it: People with active cancer or a strong family history of cancer, pregnant or breastfeeding women, and anyone not willing to monitor with objective testing.
Know what's working. Know what's not.
eterni connects your lab results, supplements, and retests — so you can see the trajectory, not just a snapshot.
Join the waitlist